NanoViricides Inc. (NNVC) stock prices surged by 14.50% around the time market trading commenced on September 14th, 2021. This brought the price per share up to USD$4.66 early on in the trading day.
NNVC Stock’s Licensing Completion
September 14th, 2021 saw NNVC stock announce the completion of the process of licensing the human Coronavirus field for drug development and commercialization from TheraCout Pharma Inc. The global leader in nanomedicines against viruses executed a license agreement on September 8th, 2021. This agreement was for the field, consisting of anti-viral treatments for the global coronavirus pandemic. These treatments were derived from human infections, resulting in the development of oral and pediatric drugs to fight Covid-19. The company’s proprietary treatments were designed to be effective against most variants of the virus.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Scope of Licensing
The licensed field is inclusive of antiviral drugs to treat the Covid-19 virus and its variants that have devastated the world for over a year. The license did not elicit an upfront cash payment and terms of compensation were commensurate with previous licenses. NNVC stock is facilitating the development of NV-CoV-2- and NV-CoV-2-R towards human clinical trials. The company has almost completed the essential preclinical work required to facilitate this progression.
Efficacy of NNVC Stock’s Drugs
NNVC’ stock’s broad-spectrum anti-coronavirus drugs are believed to continue to be effective despite the mutation of the virus. These mutations have hitherto resulted in several variants of concern. These variations have negatively impacted the antibody protection afforded by vaccines and the effectiveness of antibody drugs. The company’s unique anti-viral nanomachine technology manages to circumvent these challenges.
The company’s covid-19 drugs are also believed to be suitable for use in a pediatric context. Accordingly, NNVC stock plans to include pediatric cohorts into clinical trials at appropriate stages. The possibility of pediatric use of the drugs is based on the stellar safety profile indicated by animal studies. Pediatric infections and their severity have continued to increase as variants of Covid-19 continue to evolve.
Future Outlook for NNVC Stock
With the world hurtling towards universal immunizations, NNVC stock is poised to capitalize on the burgeoning market. The company is keen to spearhead the commercialization and proliferation of its proprietary treatments. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value.